Letter to the Editor
Why choose cyclosporin A as first-line therapy in COVID-19 pneumonia
¿Por qué elegir ciclosporina A como primera línea terapéutica para la neumonía causada por COVID-19?
Leído
4775
Vecesse ha leído el artículo
1420
Total PDF
3355
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 11 | 107 | 29 | 136 |
| 2025 10 | 21 | 52 | 73 |
| 2025 9 | 0 | 43 | 43 |
| 2025 8 | 0 | 51 | 51 |
| 2025 7 | 0 | 44 | 44 |
| 2025 6 | 9 | 18 | 27 |
| 2025 5 | 147 | 67 | 214 |
| 2025 4 | 101 | 20 | 121 |
| 2025 3 | 125 | 32 | 157 |
| 2025 2 | 82 | 37 | 119 |
| 2025 1 | 66 | 32 | 98 |
| 2024 12 | 42 | 36 | 78 |
| 2024 11 | 74 | 44 | 118 |
| 2024 10 | 24 | 20 | 44 |
| 2024 9 | 46 | 21 | 67 |
| 2024 8 | 70 | 38 | 108 |
| 2024 7 | 56 | 35 | 91 |
| 2024 6 | 67 | 29 | 96 |
| 2024 5 | 61 | 18 | 79 |
| 2024 4 | 55 | 24 | 79 |
| 2024 3 | 75 | 24 | 99 |
| 2024 2 | 49 | 27 | 76 |
| 2024 1 | 84 | 21 | 105 |
| 2023 12 | 65 | 30 | 95 |
| 2023 11 | 69 | 31 | 100 |
| 2023 10 | 76 | 29 | 105 |
| 2023 9 | 94 | 43 | 137 |
| 2023 8 | 45 | 13 | 58 |
| 2023 7 | 56 | 26 | 82 |
| 2023 6 | 38 | 35 | 73 |
| 2023 5 | 51 | 24 | 75 |
| 2023 4 | 34 | 19 | 53 |
| 2023 3 | 66 | 26 | 92 |
| 2023 2 | 49 | 30 | 79 |
| 2022 1 | 33 | 15 | 48 |
| 2022 12 | 78 | 50 | 128 |
| 2022 11 | 77 | 37 | 114 |
| 2022 10 | 108 | 32 | 140 |
| 2022 9 | 95 | 37 | 132 |
| 2022 8 | 85 | 38 | 123 |
| 2022 7 | 72 | 43 | 115 |
| 2022 6 | 82 | 44 | 126 |
| 2022 5 | 81 | 40 | 121 |
| 2022 4 | 54 | 2 | 56 |
| 2022 3 | 56 | 2 | 58 |
| 2022 2 | 55 | 2 | 57 |
| 2021 1 | 220 | 2 | 222 |
| 2021 12 | 203 | 4 | 207 |
| 2021 11 | 52 | 4 | 56 |
Mostrar todo
